Trial Profile
Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Vinblastine
- Indications Adenocarcinoma; Bladder cancer; Clear cell sarcoma; Giant cell tumours; Glandular and epithelial neoplasms; Plasmacytoma; Sarcoma; Squamous cell cancer; Trophoblastic tumour; Urogenital cancer
- Focus Adverse reactions
- 18 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2023 Results assessing effect of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer presented at the 2023 Genitourinary Cancers Symposium
- 25 Mar 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.